Acetyl-CoA carboxylase inhibitors - Pipeline Insight, 2024

This “Acetyl-CoA Carboxylase Inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Acetyl-CoA Carboxylase Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Acetyl-CoA Carboxylase Inhibitors Understanding

Acetyl-CoA Carboxylase Inhibitors: Overview

Acetyl-CoA carboxylase (ACC) is a biotin-dependent enzyme that catalyzes the irreversible carboxylation of acetyl-CoA to produce malonyl-CoA through its two catalytic activities, biotin carboxylase (BC) and carboxyltransferase (CT). ACC is a multi-subunit enzyme in most prokaryotes and in the chloroplasts of most plants and algae, whereas it is a large, multi-domain enzyme in the cytoplasm of most eukaryotes. The most important function of ACC is to provide the malonyl-CoA substrate for the biosynthesis of fatty acids.

Function - Acetyl-CoA carboxylase catalyzes the carboxylation of acetyl-CoA to malonyl-CoA. Hydrolysis of ATP provides the energy to drive this essentially irreversible reaction. Acetyl-CoA carboxylase is considered the key regulatory enzyme in the conversion of citrate to long-chain fatty acids because (i) the concentrations of its substrates and products are far from thermodynamic equilibrium; (ii) the maximum velocity of the enzyme, as measured in cell extracts under optimal conditions, is usually the slowest of all enzymes in the pathway; (iii) the concentration of the product of the enzyme, malonyl-CoA, increases when flux through the pathway increases.

Acetyl-CoA Carboxylase Inhibitors - With the accumulation of information on the ACC functions and structures in the last decade, a variety of ACC inhibitors have been identified, some of which have been approved for clinical trials.

Acetyl-CoA Carboxylase Inhibitors Emerging Drugs Chapters

This segment of the Acetyl-CoA Carboxylase Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acetyl-CoA Carboxylase Inhibitors Emerging Drugs

Firsocostat: Gilead Sciences Firsocostat is being developed by Gilead Sciences for the treatment of Non-alcoholic fatty liver disease and Non-alcoholic steatohepatitis. The drug is currently in phase 2 of clinicaltrials.

Clesacostat: Pfizer Clesacostat is an Acetyl-CoA carboxylase inhibitor developed by Pfizer for the treatment of Non-alcoholic fatty liver disease and Non-alcoholic steatohepatitis. The drug is currently in phase 2 of clinicaltrials.

Acetyl-CoA Carboxylase Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Acetyl-CoA Carboxylase Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Acetyl-CoA Carboxylase Inhibitors

There are approx. 3+ key companies which are developing the Acetyl-CoA Carboxylase Inhibitors. The companies which have their Acetyl-CoA Carboxylase Inhibitors drug candidates in the most advanced stage, i.e. phase II include, Gilead Sciences.

Phases

This report covers around 3+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Acetyl-CoA Carboxylase Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acetyl-CoA Carboxylase Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acetyl-CoA Carboxylase Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acetyl-CoA Carboxylase Inhibitors drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Acetyl-CoA Carboxylase Inhibitors R&D. The therapies under development are focused on novel approaches for Acetyl-CoA Carboxylase Inhibitors.

Acetyl-CoA Carboxylase Inhibitors Report Insights

• Acetyl-CoA Carboxylase Inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Acetyl-CoA Carboxylase Inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Acetyl-CoA Carboxylase Inhibitors drugs?
• How many Acetyl-CoA Carboxylase Inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Acetyl-CoA Carboxylase Inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Acetyl-CoA Carboxylase Inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acetyl-CoA Carboxylase Inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Gilead Sciences
• Pfizer
• Akanocure Pharmaceuticals
• Novo Nordisk

Key Products

• Firsocostat
• Clesacostat
• AK 1225

Research programme: acetyl CoA carboxylase 1/2 allosteric inhibitors- GS 834356


This product will be delivered within 2 business days.